Sugi Predict

Sugi Predict / Compounds / SCHEMBL3140900

SCHEMBL3140900

SCHEMBL3140900

COc1cnccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ CYP1A2 P05177 4/20 0.36
▸ CYP2C19 P33261 4/20 0.36
▸ CYP2E1 P05181 3/20 0.36
▸ CYP2A6 P11509 3/20 0.36
▸ CYP2B6 P20813 3/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ UCHL1 P09936 1/20 0.35
▸ EGFR P00533 2/20 0.35
▸ MAOA P21397 2/20 0.35
▸ CYP2D6 P10635 2/20 0.33
▸ CYP2C8 P10632 1/20 0.33
▸ CSF1R P07333 1/20 0.32
▸ LPL P06858 2/20 0.32
▸ LIPG Q9Y5X9 2/20 0.32
▸ CHRNB4 P30926 2/20 0.31
▸ CHRNA3 P32297 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30623051 1.00 CA12 (0.36) CA12CA1CA2CA9CYP1A2
SCHEMBL24226216 0.87 CYP1A2 (0.33) CA12CA1CA2CA9CYP1A2
SCHEMBL30494157 0.87 CA12 (0.39) CA12CA1CA2CA9CYP1A2
SCHEMBL12435832 0.87 CA12 (0.39) CA12CA1CA2CA9CYP1A2
SCHEMBL20295324 0.86 CA12 (0.40) CA12CA1CA2CA9UCHL1
SCHEMBL16052939 0.85 BUB1 (0.36) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL31710599 0.81 LPL (0.31) LPLLIPGGAA
SCHEMBL29129376 0.80 IKBKB (0.33) UCHL1CHUK
SCHEMBL29987117 0.80 IKBKB (0.33) UCHL1CHUK
SCHEMBL15717180 0.80 CHRNB4 (0.41) CHRNB4CHRNA3CHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492194-B2 HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-09 — — US disclosed
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 — — EP disclosed
WO-2025045746-A1 PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2025-03-06 — — WO disclosed
CN-117447475-A Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors H.隆德贝克有限公司 2024-01-26 — — CN disclosed
CN-117279896-A Amino substituted pyrido ring compounds, preparation method and application thereof 劲方医药科技(上海)有限公司 2023-12-22 — — CN disclosed
WO-2023213882-A1 IRREVERSIBLE MUTEGFR INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-11-09 — — WO disclosed
CN-111511742-B Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors H.隆德贝克有限公司 2023-10-27 — — CN disclosed
US-11535611-B2 Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors H. LUNDBECK A/S (DK) 2022-12-27 — — US disclosed
WO-2022214044-A1 AMINE-SUBSTITUTED PYRIDINE FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF 劲方医药科技(上海)有限公司 2022-10-13 — — WO disclosed
US-20220177458-A1 HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2022-06-09 — — US disclosed
WO-2013185284-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBOTT LABORATORIES (US) 2013-12-19 — — WO disclosed
WO-2013188381-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBVIE INC. (US) 2013-12-19 — — WO disclosed
US-20130331382-A1 Pyridinone and Pyridazinone Derivatives ABBVIE INC. 2013-12-12 — — US disclosed
WO-2013150036-A1 NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI (FR) 2013-10-10 — — WO disclosed
US-20130261106-A1 NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI (FR) 2013-10-03 — — US disclosed
US-20100004236-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2010-01-07 — — US disclosed
EP-1529049-B1 DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARM CORP (US) 2009-11-18 — — EP disclosed
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2008-06-12 — — US disclosed
US-7332486-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2008-02-19 — — US disclosed
US-20070093510-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093510-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE3B, PDE3A CA12 4308/4885CA1 3747/4885CA2 1119/4885
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE3A CA12 4308/4885CA1 3747/4885CA2 1119/4885
US-20220177458-A1 HPK1 INHIBITORS PGK1, PCK1, PDXK CA12 4633/4885CA1 4249/4885CA2 3741/4885
US-20130261106-A1 NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF DPYD, TYMP, DHFR CA12 4778/4885CA1 4866/4885CA2 4525/4885
US-20100004236-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE3A CA12 4308/4885CA1 3747/4885CA2 1119/4885
US-11535611-B2 Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors PDE5A, PDE12, PDE3A CA12 4168/4885CA1 2129/4885CA2 1775/4885
US-20130331382-A1 Pyridinone and Pyridazinone Derivatives CYP4F3, CYP4B1, CYP4F11 CA12 4860/4885CA1 4869/4885CA2 4793/4885
US-12492194-B2 HPK1 inhibitors PGK1, PCK1, PDXK CA12 4633/4885CA1 4249/4885CA2 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.